180 related articles for article (PubMed ID: 17826091)
1. Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
Li J; Ma Z; Chapo K; Yan D; Lynch AS; Ding CZ
Bioorg Med Chem Lett; 2007 Oct; 17(20):5510-3. PubMed ID: 17826091
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.
Kim IH; Combrink KD; Ma Z; Chapo K; Yan D; Renick P; Morris TW; Pulse M; Simecka JW; Ding CZ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1181-4. PubMed ID: 17189695
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.
Rothstein DM; Farquhar RS; Sirokman K; Sondergaard KL; Hazlett C; Doye AA; Gwathmey JK; Mullin S; van Duzer J; Murphy CK
Antimicrob Agents Chemother; 2006 Nov; 50(11):3658-64. PubMed ID: 16940074
[TBL] [Abstract][Full Text] [Related]
5. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
Combrink KD; Denton DA; Harran S; Ma Z; Chapo K; Yan D; Bonventre E; Roche ED; Doyle TB; Robertson GT; Lynch AS
Bioorg Med Chem Lett; 2007 Jan; 17(2):522-6. PubMed ID: 17070048
[TBL] [Abstract][Full Text] [Related]
6. The antibacterial activity of a new 3-azinomethyl-rifamycin.
Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
[TBL] [Abstract][Full Text] [Related]
7. Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
Wiles JA; Song Y; Wang Q; Lucien E; Hashimoto A; Cheng J; Marlor CW; Ou Y; Podos SD; Thanassi JA; Thoma CL; Deshpande M; Pucci MJ; Bradbury BJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1277-81. PubMed ID: 16337789
[TBL] [Abstract][Full Text] [Related]
8. In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus.
Osburne MS; Rothstein DM; Farquhar R; Murphy CK
J Antibiot (Tokyo); 2006 Feb; 59(2):80-5. PubMed ID: 16629407
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.
Tsuji BT; Yang JC; Forrest A; Kelchlin PA; Smith PF
J Antimicrob Chemother; 2008 Jul; 62(1):156-60. PubMed ID: 18400804
[TBL] [Abstract][Full Text] [Related]
10. Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Ma Z; Lynch AS
J Med Chem; 2016 Jul; 59(14):6645-57. PubMed ID: 27336583
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and potent antibacterial activity against MRSA of some novel 1,2-disubstituted-1H-benzimidazole-N-alkylated-5-carboxamidines.
Göker H; Ozden S; Yildiz S; Boykin DW
Eur J Med Chem; 2005 Oct; 40(10):1062-9. PubMed ID: 15992965
[TBL] [Abstract][Full Text] [Related]
12. Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA.
Sanchez CJ; Shiels SM; Tennent DJ; Hardy SK; Murray CK; Wenke JC
Clin Orthop Relat Res; 2015 Sep; 473(9):2874-84. PubMed ID: 25896136
[TBL] [Abstract][Full Text] [Related]
13. Triketones active against antibiotic-resistant bacteria: synthesis, structure-activity relationships, and mode of action.
van Klink JW; Larsen L; Perry NB; Weavers RT; Cook GM; Bremer PJ; MacKenzie AD; Kirikae T
Bioorg Med Chem; 2005 Dec; 13(24):6651-62. PubMed ID: 16140015
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, potent anti-staphylococcal activity and QSARs of some novel 2-anilinobenzazoles.
Ozden S; Atabey D; Yildiz S; Göker H
Eur J Med Chem; 2008 Jul; 43(7):1390-402. PubMed ID: 18022733
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of novel rifamycins against gram-positive clinical isolates.
Murphy CK; Karginova E; Sahm D; Rothstein DM
J Antibiot (Tokyo); 2007 Sep; 60(9):572-6. PubMed ID: 17917240
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel oxazolidinone antimicrobial agents.
Ebner DC; Culhane JC; Winkelman TN; Haustein MD; Ditty JL; Ippoliti JT
Bioorg Med Chem; 2008 Mar; 16(5):2651-6. PubMed ID: 18077175
[TBL] [Abstract][Full Text] [Related]
18. Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.
Osburne MS; Murphy CK; Rothstein DM
J Antibiot (Tokyo); 2006 May; 59(5):303-8. PubMed ID: 16883781
[TBL] [Abstract][Full Text] [Related]
19. Cyclopentanone ring-cleaved pleuromutilin derivatives.
Springer DM; Bunker A; Luh BY; Sorenson ME; Goodrich JT; Bronson JJ; DenBleyker K; Dougherty TJ; Fung-Tomc J
Eur J Med Chem; 2007 Jan; 42(1):109-13. PubMed ID: 17156897
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
